Table 3.
Comparison of outcomes of COVID-19 among the three groups.
| Outcomes | Absolute Lymphocyte Counts (Total n = 770) | p-Value | ||
|---|---|---|---|---|
| Group I, <500/mm3 (n = 110) |
Group II,≥500–<1000/mm3 (n = 330) |
Group III ≥1000/mm3 (n = 330) |
||
| Death, no (%) | 44 (40%) | 75 (22.7%) | 45 (13.0%) | <0.001 |
| Requirement of invasive ventilation, no (%) | 45 (40.9%) | 80 (24.5%) | 49 (14.8%) | <0.001 |
| Requirement of intensive oxygen supplements #, no (%) | 52 (47.3%) | 105 (31.8%) | 60 (18.2%) | <0.001 |
| Requirement of oxygen supplements, no (%) | 80 (72.7%) | 183 (55.5%) | 113 (34.2%) | <0.001 |
| Total hospitalized period, days, mean ± SD | 23.4 ± 13.9 | 25.5 ± 13.4 | 26.3 ± 11.8 | 0.120 |
| Survival periods since admission for patients who died, days, mean ± SD | 14.5 ± 13.3 | 16.4 ± 13.6 | 15.6 ± 14.4 | 0.764 |
| Hospitalized periods for alive patient, days, mean ± SD | 29.4 ± 10.8 | 28.2 ± 12.1 | 28.0 ± 10.5 | 0.631 |
Abbreviation: SD, standard deviation; # Intensive oxygen supply was accounted for when the subject used a facial mask, non-invasive ventilation, or high flow oxygen therapy for supplements of oxygen.